Change in Skin Elasticity With RF and PEMF

Not Applicable

Completed

Brief Summary: This study will measure the difference in skin elasticity in females only before and after treatment with radiofrequency and pulsed electromagnetic field therapy.

Detailed Description: This study is an open-label, baseline-controlled, single-center study to measure the change in skin elasticity after combined radio frequency (RF) and pulsed electromagnetic field (PEMF) treatment. Forty-five adult females will undergo weekly treatments over a period of 8 weeks. Skin elasticity will be measured by a Cutometer® prior to beginning treatment, week 7 and 3 months after completion of treatment. Photographs will be taken prior to treatment, at week 4, week 7 and 3 months after completion of treatment. Patient discomfort/pain and satisfaction questionnaires will be completed before, during and after treatment.

Recruitment & Eligibility

Inclusion Criteria

Healthy adult female subject, 18 years of age and older with Fitzpatrick skin types I-IV
Ability to tolerate the RF/PEMF procedure, and willing to adhere to the treatment regimen

Exclusion Criteria

Having any active electrical implant or permanent implant anywhere in the body, e.g. pacemaker, internal defibrillator
Prior use of retinoids in treated area within 2 weeks of initial treatment
Use of oral Isotretinoin (Accutane®) within 6 months of initial treatment
Patient on systemic corticosteroid therapy 6 months prior to start of study
Prior use of collagen, fat injections and /or other methods of skin augmentation (enhancement with injected or implanted material) in treated area within 4-6 weeks of initial treatment. Treatment may not be performed at all over permanent dermal implants.
Prior ablative resurfacing procedure in treated area with laser or other devices within 12 months of initial treatment
Any other surgery in treated area within 12 months of initial treatment
History of keloid formation or poor wound healing in a previously injured skin area
Epidermal or dermal disorders
Open laceration or abrasion of any sort on the area to be treated.
History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications.
Having any form of active cancer at the time of enrollment
Significant concurrent illness, such as uncontrolled diabetes i.e. any disease state that in the opinion of the Investigator would interfere with the treatment, or healing process
Participation in a study of another device or drug within 1 month prior to study enrollment
Tattoos in the treatment area.

Primary Outcome Measures

Name	Time	Method
Change in Facial Skin Elasticity	20 weeks after the last study treatment	A Cutometer® will be used to measure the change in gross elasticity (R2) of the facial skin as calculated by Ua/Uf which is a ratio of maximum recovery (Ua) and skin distensibility (Uf). The value is expressed as a percentage, the closer the value is to 1 (100%), the more elastic the skin.

Secondary Outcome Measures

Name	Time	Method
Improvement in Subject Satisfaction With Facial Skin Laxity Compared to Baseline as Measured by the 5-point Likert Satisfaction Scale	7 weeks and 20 weeks post study treatments	Subject will assign a score that best represents the level of satisfaction they have in their appearance as a result of the study treatment. The scale reports five categories - 4 - very satisfied; 3 - satisfied; 2 - having no opinion; 1 - unsatisfied and 0 - very unsatisfied. The higher the score, the more satisfaction with the treatment that a subject reports.
General Aesthetic Improvement Scale (GAIS)	7 weeks and 20 weeks post study treatments.	Subject to assess their general improvement in appearance at 7 and 20 weeks post-intervention using a 7 category scale: 3 - very much improved; 2 - much improved; 1 - improved; 0 - no change; -1 - worse; -2 - much worse and -3 very much worse. The higher the positive score, the more the subject feels their appearance has changed for the better.